Karolinska Institute scientists have
found a way to attack glioblastoma multiforme-one of the most deadly forms of
brain cancer-by inducing an unconventional cell death pathway that triggers
catastrophic vacuolization.1 The team identified a small molecule
that prolonged survival in a mouse model of glioblastoma without affecting
normal brain tissue, but it will likely need to combine the compound with a
conventional anticancer agent to translate it for clinical use.
told SciBX that he believes vacquinol-1 would be a good addition to the
GBM armamentarium because the compound can act on cells with different
proliferation rates, whereas temozolomide and
radiotherapy act primarily on rapidly dividing cells.
T. SciBX 7(14); doi:10.1038/scibx.2014.391
Published online April 10, 1014
1. Kitambi, S.S. et al. Cell; published online March 18,
Contact: Patrik Ernfors, Karolinska Institute, Stockholm,
2. Dolecek, T.A. et al. Neuro-oncol. 14,
3. Dent, P. et al. Cancer Biol. Ther. 7,
4. Polivka, J. Jr. et al. Anticancer Res. 32,
5. Kaul, A. et al. Cell Signal. 19, 1034-1043
6. Overmeyer, J.H. et al. Mol. Cancer Res. 6, 965-977 (2008)
7. Robinson, M.W. et al. J. Med. Chem. 55,
8. Trabbic, C.J. et al. ACS Med. Chem. Lett. 5, 73-77 (2014)
COMPANIES AND INSTITUTIONS MENTIONED
Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y.
Cancer Research Technology Ltd., London, U.K.
Emcure Pharmaceuticals Ltd., Pune, India
Karolinska Institute, Stockholm, Sweden
Karolinska Institute Innovations AB, Stockholm, Sweden
Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J.
Reliance Life Sciences, Rabale, India
The University of Alabama at Birmingham School of Medicine, Birmingham, Ala.
Virginia Commonwealth University, Richmond, Va.